Premium
Treatment of high risk Sertoli–Leydig cell tumors of the ovary using a gonadotropin releasing hormone (GnRH) analog
Author(s) -
Lashkari Harsha Prasada,
Nash Ruth,
Albanese Assunta,
Okoye Bruce,
Millar Robert,
PritchardJones Kathy
Publication year - 2013
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.24382
Subject(s) - medicine , gonadotropin releasing hormone , leuprorelin , ovary , oncology , leydig cell , chemotherapy , hormone , cancer research , luteinizing hormone
Abstract Sertoli–Leydig cell tumors are rare ovarian neoplasms. We report two unusual cases with bilateral SLCTs suggesting evidence of genetic predisposition and at high risk of recurrence. To reduce this risk, we exploited the use of GnRH analog to lower gondadotropin and potentially directly inhibit the tumors through expressed GnRH receptors. We used it as maintenance antitumor therapy for 2 years after completion of chemotherapy, to cover the period of risk for recurrence. Both patients remain in complete remission at >2 years after completing leuprorelin therapy. Of note, both patients carry DICER1 mutations, frequently found in pleuropulmonary blastoma syndrome. Pediatr Blood Cancer 2013; 60: E16–E18. © 2012 Wiley Periodicals, Inc.